ENZO BIOCHEM INC (ENZ) Stock Price, Quote, News and Overview
NYSE:ENZ - New York Stock Exchange, Inc. - US2941001024 - Common Stock - Currency: USD
ENZ Quote, Performance and Key Statistics
NYSE:ENZ (2/21/2025, 8:15:51 PM)
0.5164
-0.01 (-2.07%)
The current stock price of ENZ is 0.5164 USD. In the past month the price decreased by -21.52%. In the past year, price decreased by -62.58%.
ENZ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
| CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
| LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
| DVA | DAVITA INC | 14.99 | 11.68B | ||
| HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
| CHE | CHEMED CORP | 23.84 | 8.18B | ||
| CRVL | CORVEL CORP | 25.97 | 5.57B | ||
| OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
| GH | GUARDANT HEALTH INC | N/A | 5.30B |
Related stock screener links
About ENZ
Company Profile
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company is headquartered in Farmingdale, New York and currently employs 125 full-time employees. The firm's primary business is conducted through its Life Sciences division, Enzo Life Sciences, which is focused on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins. Its products are used to label, detect and visualize a biological target of interest in drug discovery exploration and drug development process development. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The firm monetizes its technology primarily via sales through its global distribution network and licensing. The firm conducts its research and other product development efforts through internal research and collaborative relationships.
Company Info
ENZO BIOCHEM INC
60 Executive Blvd
Farmingdale NEW YORK 10022 US
CEO: Elazar Rabbani
Employees: 185
Company Website: https://www.enzo.com/
Investor Relations: http://www.enzo.com/corporate/investor-information
Phone: 15167555500
ENZO BIOCHEM INC / ENZ FAQ
What is the stock price of ENZO BIOCHEM INC today?
The current stock price of ENZ is 0.5164 USD. The price decreased by -2.07% in the last trading session.
What is the ticker symbol for ENZO BIOCHEM INC stock?
The exchange symbol of ENZO BIOCHEM INC is ENZ and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is ENZ stock listed?
ENZ stock is listed on the New York Stock Exchange, Inc. exchange.
What is ENZO BIOCHEM INC worth?
ENZO BIOCHEM INC (ENZ) has a market capitalization of 26.98M USD. This makes ENZ a Nano Cap stock.
How many employees does ENZO BIOCHEM INC have?
ENZO BIOCHEM INC (ENZ) currently has 185 employees.
What are the support and resistance levels for ENZO BIOCHEM INC (ENZ) stock?
ENZO BIOCHEM INC (ENZ) has a resistance level at 1.11. Check the full technical report for a detailed analysis of ENZ support and resistance levels.
Should I buy ENZO BIOCHEM INC (ENZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENZ, evaluating the profitability, health, valuation and growth aspects
- ENZO BIOCHEM INC (ENZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENZO BIOCHEM INC (ENZ) Sales and EPS estimates to see what analysts future expectations are.
- ENZO BIOCHEM INC (ENZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENZO BIOCHEM INC (ENZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENZO BIOCHEM INC (ENZ) Stock Chart to make your own analysis
- ENZO BIOCHEM INC (ENZ) Latest news and press-releases to stay up to date.
Does ENZO BIOCHEM INC (ENZ) stock pay dividends?
ENZO BIOCHEM INC (ENZ) has a dividend yield of 19.36%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of ENZ dividend history, reliability and sustainability.
When does ENZO BIOCHEM INC (ENZ) report earnings?
ENZO BIOCHEM INC (ENZ) will report earnings on 2025-03-17.
What is the Price/Earnings (PE) ratio of ENZO BIOCHEM INC (ENZ)?
ENZO BIOCHEM INC (ENZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
What is the Short Interest ratio of ENZO BIOCHEM INC (ENZ) stock?
The outstanding short interest for ENZO BIOCHEM INC (ENZ) is 0.73% of its float. Check the ownership tab for more information on the ENZ short interest.
ENZ Technical Analysis
ENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENZ. While ENZ seems to be doing ok healthwise, there are quite some concerns on its profitability.
ENZ Financial Highlights
Over the last trailing twelve months ENZ reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS decreased by -68.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.33% | ||
| ROE | -47.92% | ||
| Debt/Equity | 0 |
ENZ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ENZ. The Buy consensus is the average rating of analysts ratings from 5 analysts.